BIOMARKER:

HER-2 mutation

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) neratinib Sensitive : C2 ESMO 2022 - 3wk	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks neratinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) trastuzumab + pertuzumab Sensitive : C2 ESMO 2022 - 3wk	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks trastuzumab + pertuzumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	afatinib Resistant: A2 - Guideline afatinib Resistant : A2	afatinib Resistant: A2 - Guideline afatinib Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Hormone Receptor Positive Breast Cancer	HER-2 mutation	Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Urothelial Cancer	HER-2 mutation	Urothelial Cancer	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3
HER-2 mutation	Lung Adenocarcinoma	HER-2 mutation	Lung Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
HER-2 mutation	Thymic Carcinoma	HER-2 mutation	Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
HER-2 mutation	Lung Adenocarcinoma	HER-2 mutation	Lung Adenocarcinoma	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
HER-2 mutation	HER2 Positive Breast Cancer	HER-2 mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
HER-2 mutation	Lung Adenocarcinoma	HER-2 mutation	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 mutation	HER2 Positive Breast Cancer	HER-2 mutation	HER2 Positive Breast Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3

HER-2 mutation

Associations